WallStSmart
CLYM

Climb Bio Inc

NASDAQ: CLYM · HEALTHCARE · BIOTECHNOLOGY

$11.17
-3.30% today

Updated 2026-06-05

Market cap
$597.83M
P/E ratio
P/S ratio
EPS (TTM)
$-0.77
Dividend yield
52W range
$1 – $12
Volume
0.8M

Climb Bio Inc (CLYM) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2019202020212022202320242025
Operating cash flow$-5.01M$-14.10M$-36.07M$-37.37M$-20.60M$-15.56M$-54.36M
Capital expenditures$0.00$0.00$0.00$0.00$0.00$0.00$186000.00
Depreciation
Stock-based comp$707000.00$3.74M$6.99M$12.81M$5.56M$8.05M
Free cash flow$-5.01M$-14.10M$-36.07M$-37.37M$-20.60M$-15.56M$-54.54M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does CLYM generate?

CLYM produced $-54.54M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CLYM's balance sheet healthy?

CLYM holds $35.69M in cash and equivalents against — in long-term debt, on $160.47M of shareholder equity. That debt is best read against the cash flow the business throws off each year.